In a phase I study, the c-MET inhibitor tivantinib was given in combination with gemcitabine in patients with advanced or metastatic solid tumors including 8 cases of CCA.19 Of the 49 evaluable patients, 39% were strongly positive for MET expression by IHC. This evidence concerns the gene MET and cholangiocarcinoma.